Trials / Completed
CompletedNCT01432717
Study of ACE-536 in Healthy Postmenopausal Women
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-536 in Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · Industry
- Sex
- Female
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to find out whether ACE-536 can be safely given to patients. This study will also look to see if ACE-536 increases red blood cells, the cells that carry oxygen in the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ACE-536 | Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15. |
| OTHER | Placebo | Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15. |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2012-09-01
- Completion
- 2012-10-01
- First posted
- 2011-09-13
- Last updated
- 2012-11-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01432717. Inclusion in this directory is not an endorsement.